Date published: 2026-5-17

1-800-457-3801

SCBT Portrait Logo
Seach Input

OTTMUSG00000011275 Activators

Interferon Alpha 16 (IFNA16) is a type I interferon, a group of proteins known for their critical role in the immune response, particularly in antiviral defense. The IFNA16 protein, encoded by the Ifna16 gene, is part of a larger family of interferons that are key players in the innate immune system. These proteins are typically produced in response to the presence of pathogens, such as viruses, and serve to initiate a robust antiviral state in cells. The activation and subsequent signaling pathways of type I interferons, including IFNA16, are crucial for the modulation of immune responses, influencing both innate and adaptive immunity. The activation of IFNA16, like other type I interferons, is intricately linked to the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs). These receptors, including Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs), detect viral components such as double-stranded RNA (dsRNA) and trigger signaling cascades that lead to the production of interferons. Upon activation, IFNA16 engages with its receptor, initiating the JAK-STAT signaling pathway. This pathway results in the transcription of numerous interferon-stimulated genes (ISGs), which encode proteins that interfere with viral replication and modulate immune responses.

The proposed chemicals in the table are hypothesized to influence the activation of IFNA16 indirectly by modulating pathways that are upstream of IFNA16 expression and function. For example, TLR agonists such as Poly(I:C), Imiquimod, and Resiquimod activate specific TLRs, leading to downstream signaling events that culminate in the production of type I interferons. Similarly, compounds that affect endosomal acidification, like Chloroquine and Bafilomycin A1, can modulate TLR signaling, potentially impacting IFNA16 activation. These indirect activators do not directly interact with IFNA16 but influence the cellular environment and signaling pathways that are conducive to its activation. In summary, the activation of IFNA16 is a complex process involving multiple layers of regulation, primarily initiated by the detection of viral components and culminating in a potent antiviral response. Understanding the intricacies of IFNA16 activation and its regulation is crucial for comprehending the broader aspects of immune signaling and response to viral infections.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Polyinosinic-polycytidylic acid potassium salt

31852-29-6sc-202767
5 mg
$198.00
(1)

Polyinosinic:polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA (dsRNA). It activates Toll-like receptor 3 (TLR3), leading to the activation of IRF3 and NF-κB, which can promote the expression of type I interferons including IFNA16. This suggests Poly(I:C) could indirectly activate IFNA16 through TLR3-mediated pathways.

Imiquimod

99011-02-6sc-200385
sc-200385A
100 mg
500 mg
$67.00
$284.00
6
(1)

Imiquimod is an immune response modifier that activates Toll-like receptor 7 (TLR7). This activation can lead to the induction of type I interferon responses. Imiquimod’s role in stimulating TLR7 suggests it could indirectly activate IFNA16 through the TLR7 signaling pathway.

Gardiquimod

1020412-43-4sc-221663
sc-221663A
sc-221663B
sc-221663C
sc-221663D
sc-221663E
sc-221663F
25 mg
50 mg
100 mg
250 mg
5 g
10 g
25 g
$157.00
$282.00
$516.00
$1177.00
$20138.00
$32779.00
$70753.00
1
(1)

Gardiquimod is a selective TLR7 agonist, which can induce type I interferon production. Gardiquimod’s activation of TLR7 implies a potential for indirect activation of IFNA16 through the TLR7 signaling cascade.

R-848

144875-48-9sc-203231
sc-203231A
sc-203231B
sc-203231C
5 mg
25 mg
100 mg
500 mg
$102.00
$306.00
$510.00
$1559.00
12
(1)

R848, also known as Resiquimod, activates TLR7 and TLR8, stimulating type I interferon production. This suggests a potential for indirect activation of IFNA16 through TLR7/8 signaling pathways.

Loxoribine

121288-39-9sc-203118
sc-203118A
25 mg
100 mg
$124.00
$390.00
1
(0)

Loxoribine is a selective agonist for TLR7. By activating TLR7, it can induce type I interferon responses, suggesting a potential indirect route for activating IFNA16 through TLR7-mediated signaling.

Amiloride

2609-46-3sc-337527
1 g
$296.00
7
(1)

Amiloride, a diuretic, inhibits endosomal acidification, which can impact TLR signaling pathways that lead to type I interferon production. Amiloride’s effect on endosomal acidification implies an indirect route for IFNA16 activation via modulation of TLR-mediated signaling.

Chloroquine

54-05-7sc-507304
250 mg
$69.00
2
(0)

Chloroquine, an antimalarial drug, also inhibits endosomal acidification affecting TLR signaling. Its role in modulating TLR pathways suggests an indirect mechanism for IFNA16 activation.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$98.00
$255.00
$765.00
$1457.00
280
(6)

Bafilomycin A1, an inhibitor of vacuolar-type H+-ATPase, affects endosomal acidification and TLR signaling. This suggests an indirect potential for IFNA16 activation via modulation of TLR-mediated pathways.

JAK Inhibitor I

457081-03-7sc-204021
sc-204021A
500 µg
1 mg
$156.00
$339.00
59
(1)

JAK Inhibitor I, while primarily an inhibitor, can lead to compensatory activation of alternative pathways, potentially influencing type I interferon production. This suggests an indirect potential for IFNA16 activation through modulation of JAK-STAT signaling.